India, Nov. 10 -- AstraZeneca(AZN), has acquired Omniose, a St. Louis-based preclinical biotechnology company, making it a wholly owned subsidiary within its Infectious Disease Unit.
The deal follows a three-year exclusive research collaboration and adds Omniose's proprietary bioconjugation platform for developing bacterial polysaccharide conjugate vaccines.
The technology enables vaccine components to be produced and linked within a single cell, potentially simplifying manufacturing and improving molecular precision.
AstraZeneca plans to use the platform to support vaccine development against serious bacterial infections, including those complicated by antimicrobial resistance.
googletag.cmd.push(function() { googletag.display('div-gpt...